COMMON INITIAL DOSING REGIMENS

• The typical starting dose is 50–100 mg intramuscularly every 7–14 days. Doses may be adjusted to 75–200 mg every 3-7 days based on serum testosterone levels and clinical response.

MECHANISM OF ACTION

• Testosterone cypionate is a synthetic esterified form of testosterone that is slowly released into the bloodstream after intramuscular administration. It binds to androgen receptors in target tissues, activating gene transcription and protein synthesis. This action facilitates secondary male sexual characteristics, muscle growth, bone density maintenance, and erythropoiesis.

• The long half-life of testosterone cypionate (~8 days) ensures a sustained increase in serum testosterone, making it suitable for periodic administration.

COMMON SIDE EFFECTS

• Endocrine: Gynecomastia, testicular atrophy, and suppression of endogenous testosterone production.

• Cardiovascular: Hypertension, polycythemia (elevated hematocrit), and potential increased risk of cardiovascular events.

• Dermatologic: Acne, oily skin, and hair loss due to androgenic activity.

• Metabolic: Weight gain, alterations in lipid profiles (e.g., decreased HDL), and fluid retention.

• Psychological: Mood swings, aggression, or increased libido.

• Rare: Deep vein thrombosis or pulmonary embolism in predisposed individuals.

CONTRAINDICATIONS

• Absolute: Known or suspected prostate cancer, breast cancer in men, and hypersensitivity to testosterone cypionate or its components.

• Relative: Severe heart failure, sleep apnea, erythrocytosis (hematocrit >54%), and uncontrolled hypertension. Caution is also advised in patients with a history of thromboembolic events or liver dysfunction.

MORE INFORMATION

• FDA Safety Data Sheet can be found here

• Bhasin S. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 [PubMed Link]

• Greenberg DR. Association of testosterone replacement therapy with atrial fibrillation and acute kidney injury. J Sex Med. 2024 [PubMed Link]

• Corona G. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014 [PubMed Link] 

• Lombardi G. Estrogens and health in males. Mol Cell Endocrinol. 2001 [PubMed Link] 

• Bhasin S. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 [PubMed Link]

• Winters SJ. Current status of testosterone replacement therapy in men. Arch Fam Med. 1999 [PubMed Link]

• Borst SE. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med. 2014 [PubMed Link]

• Hoffman BM. Cardiovascular disease risk, vascular health and erectile dysfunction among middle-aged, clinically depressed men. Int J Impot Res. 2010 [PubMed Link] 

• Sharma R. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015 [PubMed Link]

• Finkelstein JS. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013 [PubMed Link]

• Khera M. Adult-Onset Hypogonadism. Mayo Clin Proc. 2016 [PubMed Link]

• Mlynarz N. Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review. Int J Mol Sci. 2024 [PubMed Link]

• Mahmoud M. The Effects of Testosterone Replacement Therapy in Adult Men With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis. Clin Transl Gastroenterol. 2025 [PubMed Link]

• Grossmann M. Indications for testosterone therapy in men. Curr Opin Endocrinol Diabetes Obes. 2024 [PubMed Link]

• Dengri C. Testosterone supplementation and stroke in young adults: a review of the literature. Front Neurol. 2024 [PubMed Link]

• Cruickshank M. The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation. Health Technol Assess. 2024 [PubMed Link]

• de Silva NL. Cardiovascular disease and testosterone therapy in male hypogonadism. Ann N Y Acad Sci. 2024 [PubMed Link]

• De Silva NL. Male hypogonadism: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2024 [PubMed Link]

• Theodorakis N. Testosterone therapy for functional hypogonadism in middle-aged and elderly males: current evidence and future perspectives. Hormones (Athens). 2024 [PubMed Link]

• Gallegos JL. Testosterone replacement therapy for hypogonadism: A primer for primary care. Nurse Pract. 2024 [PubMed Link

• Pencina KM. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 [PubMed Link]